Clinical relapse of immune‐mediated thrombotic thrombocytopenic purpura following COVID‐19 vaccination

Authors: William Deucher, Senthil Sukumar, Spero R. Cataland

Source: Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 1, Pp n/a-n/a (2022)

Subject Terms: ADAMTS‐13, caplacizumab, COVID‐19, Pfizer‐BioNTech SARS‐CoV‐2 vaccine, thrombotic thrombocytopenia purpura, Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://doaj.org/toc/2475-0379

Access URL: https://doaj.org/article/2a0471bca37d4ae28c71f968d896ef13